Leonard S. Schleifer - 11 Dec 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: Bd. Co-Chair, President & CEO, Director
Signature: /s/**Leonard S. Schleifer
Issuer symbol: REGN
Transactions as of: 11 Dec 2023
Net transactions value: -$10,838,960
Form type: 4
Filing time: 13 Dec 2023, 16:05:34 UTC
Previous filing: 17 May 2023
Next filing: 15 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise		+25,155	+6.9%		387,270	11 Dec 2023	Direct	F1
transaction	REGN	Common Stock	Tax liability	$10,838,960	-12,841	-3.3%	$844.09	374,429	11 Dec 2023	Direct
holding	REGN	Common Stock						250,000	11 Dec 2023	2023 GRAT
holding	REGN	Common Stock						5,916	11 Dec 2023	By 401(k) Plan
holding	REGN	Common Stock						64,985	11 Dec 2023	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	2019 Performance Stock Units	Options Exercise		-25,155	-100%		0	11 Dec 2023	Common Stock	25,155		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended.

Content

On December 11, 2019, the reporting person was granted performance-based restricted stock units ("PSUs") representing the contingent right to receive shares of the issuer's common stock based upon the achievement of certain performance metrics related to total shareholder return ("TSR") over the applicable vesting period. On December 11, 2023, 25,155 PSUs (or the maximum number of PSUs eligible for vesting) vested in full and were automatically settled into an equal number of shares of the issuer's common stock based upon achievement of 75% cumulative TSR over the four-year performance period then ended.